Entrada Therapeutics Closes $116M Series B Financing

01 Apr, 2021

Entrada Therapeutics Closes $116M Series B Financing
Photo by OSPAN ALI on Unsplash

– Entrada Therapeutics from Boston develops intracellular biologics to treat devastating diseases.
– The company closed a $116m Series B financing.
– The round was led by Wellington Management Company and joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority (“QIA”), Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures and one undisclosed global investment firm.
– Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated in the financing.
– The new investment will be used to advance its pipeline to the clinic.

Biotechnology Emergency Medicine Genetics Health Care Medical North America
Crunchbase icon

Content report

The following text will be sent to our editors: